Testing two different doses of tiotropium Respimat® in cystic fibrosis: Phase 2 randomized trial results

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Bradley, Judy M ^a   Koker, Paul ^b   Deng, Qiqi ^b   Moroni Zentgraf, Petra ^c   Ratjen, Felix ^d   Geller, David E ^e   Stuart Elborn, J ^f  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; SCOPOLAMINE DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BRONCHITIS; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HEMOPTYSIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SINUSITIS; SOFT MIST INHALER; SPUTUM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ADULT; CLINICAL TRIAL; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE; YOUNG ADULT;

EID: 84907104599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106195     Document Type: Article

References (34)

1. Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154: 1229-1256.
2. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, et al. (1999) Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 28: 248-254.
3. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME (2003) Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 123: 20-27.
4. Colombo JL (2003) Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 9: 504-508.
5. Cropp GJ (1996) Effectiveness of bronchodilators in cystic fibrosis. Am J Med 100: 19S-29S.
6. Avital A, Sanchez I, Chernick V (1992) Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pulmonol 13: 34-37.
7. Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, et al. (2008) A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 102: 32-41.
8. Bateman E, Singh D, Smith D, Disse B, Towse L, et al. (2010) Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 5: 197-208.
9. Kamin W, Bannemer-Schult K, Klemmer A, Schulze Schweinhorst P, Wachtel H, et al. (2010) Children below five years of age can handle Respimat Soft Mist inhaler [abstract]. Am J Respir Crit Care Med 181 A6254.
10. Kamin W, Bannemer-Schult K, Klemmer A, Schulze Schweinhorst P, Wachtel H, et al. (2011) Flow profile data indicate that Respimat with spacer is suitable for inhalation therapy of pre-school children. Presented at: International Society for Aerosols in Medicine Congress; 18-22 June 2011; Rotterdam, The Netherlands.
11. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, et al. (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153: S4-S14.
12. Wang X, Dockery DW, Wypij D, Gold DR, Speizer FE, et al. (1993) Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 148: 1502-1508.
13. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725-734.
14. Henry B, Aussage P, Grosskopf C, Goehrs JM (2003) Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res 12: 63-76.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319-338.
16. Whittaker ET, Robinson G (1967) The trapezoidal and parabolic rules. The Calculus of Observations: an Introduction to Numerical Mathematics. 4th ed. Dover, New York, 156-158.
17. Goss CH, Burns JL (2007) Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62: 360-367.
18. Lymp J (2009) Pulmonary exacerbations in a phase 2 clinical trial of BIIL 284 BS in CF: development and implementation of a respiratory and systemic symptoms questionnaire (RSSQ) [abstract]. Pediatr Pulmonol S23 A221.
19. Koker P, Bhattacharya S, Staab A (2007) A randomized, double-blind, placebo controlled study to investigate the efficacy and safety of 24 weeks of oral treatment with BIIL 284 BS in adult (75 mg, 150 mg) and pediatric (75 mg) cystic fibrosis patients. Boeringher Ingelheim Report.
20. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 1: 2.
21. Ratjen F, Koker P, Geller D, Langellier-Cocteaux B, Maulf F Le, et al. (2013) Tiotropium Respimat in cystic fibrosis: efficacy and safety results of phase III randomized placebo-controlled trial [abstract]. J Cyst Fibros (Suppl 1): S64.
22. Halfhide C, Evans HJ, Couriel J (2005) Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev: CD003428.
23. Hordvik NL, Sammut PH, Judy CG, Colombo JL (1999) Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 27: 43-53.
24. Salvatore D, D'Andria M (2002) Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol 34: 11-15.
25. Hordvik NL, Sammut PH, Judy CG, Colombo JL (2002) Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 34: 287-296.
26. Ichinose M, Fujimoto T, Fukuchi Y (2010) Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 104: 228-236.
27. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, et al. (2009) The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 103: 22-29.
28. Spiriva RESPIMAT. Summary of Product Characteristics (2010) emc+ website. Available: http://www.medicines.org.uk/EMC/medicine/20134/SPC/Spiriva+Respimat+2.5+micrograms+solution+for+inhalation/. Accessed 9 June 2013.
29. Aitken ML, Bellon G, De BK, Flume PA, Fox HG, et al. (2012) Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 185: 645-652.
30. Bilton D, Bellon G, Charlton B, Cooper P, De BK, et al. (2013) Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 12: 367-376.
31. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
32. Vandyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS, et al. (2013) Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. Ann Am Thorac Soc 10: 205-212.
33. Royce FH, Carl JC (2011) Health-related quality of life in cystic fibrosis. Curr Opin Pediatr 23: 535-540.
34. Kesser KC, Geller DE (2009) New aerosol delivery devices for cystic fibrosis. Respir Care 54: 754-767.